| Nov 14 |
Passage Bio Achieves Milestones in Gene Therapy Trials
|
| Nov 13 |
Passage Bio GAAP EPS of -$0.31 misses by $0.08
|
| Nov 13 |
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
|
| Nov 6 |
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
|
| Sep 24 |
Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc
|
| Sep 23 |
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
|
| Sep 19 |
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc
|
| Sep 16 |
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
|
| Aug 6 |
Passage Bio to Participate in Upcoming Investor Conferences
|
| Aug 1 |
Passage Bio gains after licensing deal with GEMMA Bio
|
